Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortization of Deferred ChargesAmortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares IssuedShares RepurchasedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueDepreciation ExpenseEBIATGross ProfitLeasesLong-Term Debt RepaymentsMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetReceivables - OtherShares IssuedShares OutstandingShares OutstandingShares RepurchasedShort-Term Debt issuances
Ratios

Collegium Pharmaceutical (COLL) Long-Term Debt Repayments (2016 - 2026)

Collegium Pharmaceutical has reported Long-Term Debt Repayments over the past 8 years, most recently at -$48.4 million for Q4 2025.

  • For Q4 2025, Long-Term Debt Repayments fell 400.0% year-over-year to -$48.4 million; the TTM value through Sep 2025 reached $64.6 million, down 43.17%, while the annual FY2024 figure was $107.8 million, 22.23% down from the prior year.
  • Long-Term Debt Repayments for Q4 2025 was -$48.4 million at Collegium Pharmaceutical, down from $16.1 million in the prior quarter.
  • Over five years, Long-Term Debt Repayments peaked at $113.6 million in Q2 2023 and troughed at -$48.4 million in Q4 2025.
  • A 5-year average of $20.4 million and a median of $16.1 million in 2024 define the central range for Long-Term Debt Repayments.
  • Biggest five-year swings in Long-Term Debt Repayments: surged 100.0% in 2022 and later tumbled 400.0% in 2025.
  • Year by year, Long-Term Debt Repayments stood at $12.5 million in 2021, then surged by 100.0% to $25.0 million in 2022, then fell by 12.12% to $22.0 million in 2023, then fell by 26.51% to $16.1 million in 2024, then tumbled by 400.0% to -$48.4 million in 2025.
  • Business Quant data shows Long-Term Debt Repayments for COLL at -$48.4 million in Q4 2025, $16.1 million in Q3 2025, and $16.1 million in Q2 2025.